What are the recommended treatment options for irritable bowel syndrome (IBS), including dietary measures, soluble fiber, and pharmacologic therapies for diarrhea‑dominant, constipation‑dominant, and mixed subtypes?

Treatment of Irritable Bowel Syndrome

All patients with IBS should begin with regular exercise and first-line dietary advice, followed by soluble fiber (ispaghula 3-4 g/day, titrated gradually), and if symptoms persist, advance to a supervised low-FODMAP diet as second-line dietary therapy. 1

First-Line Approach: Lifestyle and Dietary Modifications

Exercise and General Lifestyle

• Advise all patients to engage in regular physical activity, as this provides benefit for global IBS symptoms (strong recommendation despite weak evidence quality). 1
• Encourage patients to identify leisure time and create dedicated relaxation periods. 1

Initial Dietary Recommendations

Provide the following specific dietary guidance to all patients 1:

• Have regular meals with adequate time to eat; avoid missing meals or long gaps between eating
• Drink at least 8 cups of fluid daily, preferring water or non-caffeinated beverages like herbal teas
• Limit tea and coffee to 3 cups per day
• Reduce alcohol and carbonated beverages
• Limit high-fiber foods (whole-meal flour, high-bran cereals, brown rice) as these may worsen symptoms
• Reduce resistant starch found in processed or recooked foods
• Limit fresh fruit to 3 portions daily (approximately 80g per portion)
• For IBS with diarrhea: avoid sorbitol (artificial sweetener in sugar-free products)
• For wind and bloating: consider oats and linseeds (up to 1 tablespoon daily)

Fiber Supplementation

• Use soluble fiber (ispaghula/psyllium) for global symptoms and abdominal pain (strong recommendation, moderate evidence). 1
• Start at low dose (3-4 g/day) and build up gradually to avoid bloating. 1
• Avoid insoluble fiber (wheat bran) as it may exacerbate symptoms. 1
• Soluble fiber is particularly appropriate for constipation-predominant IBS (IBS-C). 1

What NOT to Recommend

• Do not recommend food elimination diets based on IgG antibodies (strong recommendation, moderate evidence). 1
• Do not recommend gluten-free diet (weak recommendation, very low evidence). 1
• Discourage aloe vera for IBS treatment. 1

Second-Line Dietary Therapy: Low-FODMAP Diet

If symptoms persist despite first-line measures, implement a low-FODMAP diet under supervision of a trained dietitian. 1

Low-FODMAP Diet Structure

The diet consists of three mandatory phases 1:

1. Restriction phase (4-6 weeks maximum): Eliminate high-FODMAP foods
2. Reintroduction phase: Systematically reintroduce FODMAP foods to identify triggers
3. Personalization phase: Maintain diet based on individual tolerance

• This approach is effective for global symptoms, abdominal pain, and bloating (weak recommendation due to very low evidence quality, but network meta-analysis shows it is the most effective dietary strategy). 1
• Must be supervised by a registered dietitian to ensure proper implementation and nutritional adequacy. 1
• Studies show 62.7% of patients achieve >50-point reduction in IBS-Symptom Severity Score with low-FODMAP diet versus 40.8% with traditional dietary advice. 1

Pharmacological Therapy by Subtype

For IBS with Diarrhea (IBS-D)

First-line pharmacological options:

• Loperamide for diarrhea control (strong recommendation, very low evidence): Titrate dose carefully to avoid abdominal pain, bloating, nausea, and constipation. 1
• Rifaximin is recommended for global IBS-D symptoms (strong recommendation from ACG guidelines). 2
• Antispasmodics for global symptoms and abdominal pain (weak recommendation, very low evidence): Common side effects include dry mouth, visual disturbance, and dizziness. 1
• Eluxadoline (mixed opioid receptor drug) is efficacious for IBS-D. 1

Consider bile acid malabsorption testing in IBS-D patients with atypical features (nocturnal diarrhea, prior cholecystectomy) using SeHCAT scanning or serum 7α-hydroxy-4-cholesten-3-one. 1

For IBS with Constipation (IBS-C)

Recommended pharmacological options:

• Chloride channel activators (lubiprostone) and guanylate cyclase activators (linaclotide) for global IBS-C symptoms (strong recommendation from ACG). 2
• Secretagogues are strongly supported for IBS-C. 3
• Polyethylene glycol received conditional recommendation. 3

For All IBS Subtypes

Probiotics:

• May be effective for global symptoms and abdominal pain (weak recommendation, very low evidence). 1
• No specific species or strain can be recommended. 1
• Advise patients to trial for 12 weeks (or at least 4 weeks per NICE guidelines) and discontinue if no improvement. 1

Second-Line Pharmacological Therapy: Neuromodulators

When first-line treatments fail, advance to gut-brain neuromodulators:

Tricyclic Antidepressants (TCAs)

• TCAs are effective second-line therapy for global symptoms and abdominal pain (strong recommendation, moderate evidence). 1
• Start amitriptyline 10 mg once daily at bedtime. 1
• Titrate slowly to maximum 30-50 mg once daily. 1
• Provide careful explanation of rationale (gut-brain neuromodulation, not depression treatment). 1
• Counsel patients about side effects (sedation, dry mouth, constipation). 1
• Can be initiated in primary or secondary care. 1

Selective Serotonin Reuptake Inhibitors (SSRIs)

• SSRIs may be effective for global symptoms (weak recommendation, low evidence). 1
• Require similar counseling about rationale and side effects as TCAs. 1
• Can be initiated in primary or secondary care. 1

Psychological Therapies

Gut-directed psychotherapy is recommended for global IBS symptoms (strong recommendation from ACG). 2

Specific modalities with evidence 1, 4:

• Cognitive behavioral therapy (CBT): Suggested for persistent symptoms
• Gut-directed hypnotherapy: Suggested for refractory cases
• These are particularly important for patients unresponsive to pharmacological treatments. 5

Diagnostic Considerations Before Treatment

Essential Testing

• Perform serologic testing for celiac disease in all IBS patients, especially those with diarrhea. 2, 4
• Check fecal calprotectin in suspected IBS-D to exclude inflammatory bowel disease. 2
• Full blood count and C-reactive protein. 3

When to Perform Colonoscopy

Colonoscopy is NOT routinely indicated for IBS (strong recommendation, moderate evidence). 1

Perform colonoscopy only when 1:

• Alarm symptoms or signs are present
• IBS-D with atypical features suggesting microscopic colitis: female sex, age ≥50 years, coexistent autoimmune disease, nocturnal or severe watery diarrhea, duration <12 months, weight loss, or use of NSAIDs/PPIs

Treatment Algorithm Summary

1. Start all patients: Regular exercise + first-line dietary advice
2. Add soluble fiber: Ispaghula 3-4 g/day, titrated gradually
3. If inadequate response: Low-FODMAP diet (dietitian-supervised, 4-6 weeks restriction, then reintroduction)
4. Subtype-specific pharmacotherapy:
   • IBS-D: Loperamide, rifaximin, or antispasmodics
   • IBS-C: Linaclotide, lubiprostone, or secretagogues
   • All subtypes: Consider probiotics (12-week trial)
5. If refractory: TCAs (amitriptyline 10 mg, titrate to 30-50 mg) or SSRIs
6. Consider psychological therapy: CBT or gut-directed hypnotherapy for persistent symptoms

Common Pitfalls to Avoid

• Do not use insoluble fiber (wheat bran) as it worsens symptoms. 1
• Do not implement low-FODMAP diet without dietitian supervision to prevent nutritional deficiencies. 1
• Do not continue probiotics beyond 12 weeks if ineffective. 1
• Do not order routine colonoscopy in absence of alarm features. 1
• Do not recommend IgG-based elimination diets or gluten-free diets without celiac disease. 1